Darakhshan Parveen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Darakhshan Parveen has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Faizul Azam
Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia
2 shared publications - Mohammad Ahmed Khan
Department of Pharmacology, School of Pharmaceutical Education and Research, New Delhi, India
2 shared publications - Mohammad Mumtaz Alam
Drug Design and Medicinal Chemistry Lab, Department of Pharmaceutical Chemistry, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi, 110062, India
2 shared publications - Mohammad Shaquiquzzaman
Drug Design and Medicinal Chemistry Lab, Department of Pharmaceutical Chemistry, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi, 110062, India
2 shared publications - Mymoona Akhter
Drug Design and Medicinal Chemistry Lab, Department of Pharmaceutical Chemistry, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi, 110062, India
2 shared publications - Ruhi Ali
Department of Pharmaceutical Chemistry, DIPSAR, Delhi Pharmaceutical Science and Research University (DPSRU)
2 shared publications
Latest Publications
- 10 March 2025
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 44 (1) , 447-462
Monotherapy vs combination therapy evaluation of FDA-approved TKIs targeting PDGFR for the treatment of thyroid cancer
Thyroid cancer is the 5th most common type of cancer in the USA. There are various tyrosine kinase inhibitors (TKIs) approved by the US FDA for its treatment but all the approved drugs target receptor tyrosine kinase through different pathways. On 4th May, 2018, a combination of Dabrafenib and Trametinib/Dab-Tra has been approved by US FDA for the treatment of anaplastic thyroid cancer (ATC) that highlights the importance of combination therapy in its treatment. As this combination has some major safety concerns, it creates a need to find an alternative combination. In this manuscript, we have tested the potential of all the combinations possibly made by combining different FDA-approved TKIs against Platelet-Derived Growth Factor Receptor Alpha (PDGFRA) using simultaneous docking. We found that the best combination amongst all is of Pralsetinib and Trametinib/Pra-Tra with a docking score of -14.47 kcal/mol. MD simulation was also carried out and the RMSF and the RMSD of the protein in the bound form suggested that its Model 1 is best amongst all. These results were further strengthened using FEL. The PCA was performed that suggested the structural conformations observed beyond 60 ns are closer to a stable state. The outcome reveals that there are various combinations of TKIs that have the potential to be more efficacious for the treatment of thyroid cancer than Dab-Tra. We also found that a combinatorial approach with TKIs could prove to be better than monotherapy. Further in-vitro and in-vivo studies are required to strengthen the results obtained through in-silico experiment.
- 10 March 2025
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 44 (1) , 447-462
Monotherapy vs combination therapy evaluation of FDA-approved TKIs targeting PDGFR for the treatment of thyroid cancer
Thyroid cancer is the 5th most common type of cancer in the USA. There are various tyrosine kinase inhibitors (TKIs) approved by the US FDA for its treatment but all the approved drugs target receptor tyrosine kinase through different pathways. On 4th May, 2018, a combination of Dabrafenib and Trametinib/Dab-Tra has been approved by US FDA for the treatment of anaplastic thyroid cancer (ATC) that highlights the importance of combination therapy in its treatment. As this combination has some major safety concerns, it creates a need to find an alternative combination. In this manuscript, we have tested the potential of all the combinations possibly made by combining different FDA-approved TKIs against Platelet-Derived Growth Factor Receptor Alpha (PDGFRA) using simultaneous docking. We found that the best combination amongst all is of Pralsetinib and Trametinib/Pra-Tra with a docking score of -14.47 kcal/mol. MD simulation was also carried out and the RMSF and the RMSD of the protein in the bound form suggested that its Model 1 is best amongst all. These results were further strengthened using FEL. The PCA was performed that suggested the structural conformations observed beyond 60 ns are closer to a stable state. The outcome reveals that there are various combinations of TKIs that have the potential to be more efficacious for the treatment of thyroid cancer than Dab-Tra. We also found that a combinatorial approach with TKIs could prove to be better than monotherapy. Further in-vitro and in-vivo studies are required to strengthen the results obtained through in-silico experiment.
- 2 May 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 42 (4) , 1858-1874
Effectiveness of estrogen and its derivatives over dexamethasone in the treatment of COVID-19
Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus and dexamethasone is a glucocorticoid widely used for its treatment. Dexamethasone is not used in non-severe cases due to its immunosuppressant action. So, considering this, Estrogen and Estetrol were tested for the treatment of COVID-19 as they all possess a common steroid ring and dislike dexamethasone, they are immunoenhancer. Virtual screening of test ligands was performed through molecular docking, MM-GBSA, simulations, in silico ADMET and drug-likeness prediction to identify their potential to inhibit the effects of SARS-CoV-2. Results showed that test ligands possess drug-like properties and they are safe as drug candidates. The protein-ligand interaction study revealed that they bind with the amino acid residues at the active site of the target proteins and the test ligands possess better binding potential than Dexamethasone. With protein Mpro, Estetrol and Estrogen showed docking score of −7.240 and −5.491 kcal/mol, and with protein ACE2, Estetrol and Estrogen showed docking score of −5.269 and −4.732 kcal/mol, respectively. Further, MD Simulation was carried out and most of the interactions of molecular docking are preserved during simulation. The prominent interactions that our test ligands showed during MD Simulation are similar to drugs that possess in vitro anticovid activity as shown in recent studies. Hence, our test ligands possessed potential for anticovid activity and they should be further tested through in vitro and in vivo studies for their activity against COVID-19. Communicated by Ramaswamy H. Sarma
- 2 May 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 42 (4) , 1858-1874
Effectiveness of estrogen and its derivatives over dexamethasone in the treatment of COVID-19
Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus and dexamethasone is a glucocorticoid widely used for its treatment. Dexamethasone is not used in non-severe cases due to its immunosuppressant action. So, considering this, Estrogen and Estetrol were tested for the treatment of COVID-19 as they all possess a common steroid ring and dislike dexamethasone, they are immunoenhancer. Virtual screening of test ligands was performed through molecular docking, MM-GBSA, simulations, in silico ADMET and drug-likeness prediction to identify their potential to inhibit the effects of SARS-CoV-2. Results showed that test ligands possess drug-like properties and they are safe as drug candidates. The protein-ligand interaction study revealed that they bind with the amino acid residues at the active site of the target proteins and the test ligands possess better binding potential than Dexamethasone. With protein Mpro, Estetrol and Estrogen showed docking score of −7.240 and −5.491 kcal/mol, and with protein ACE2, Estetrol and Estrogen showed docking score of −5.269 and −4.732 kcal/mol, respectively. Further, MD Simulation was carried out and most of the interactions of molecular docking are preserved during simulation. The prominent interactions that our test ligands showed during MD Simulation are similar to drugs that possess in vitro anticovid activity as shown in recent studies. Hence, our test ligands possessed potential for anticovid activity and they should be further tested through in vitro and in vivo studies for their activity against COVID-19. Communicated by Ramaswamy H. Sarma